Many of the pharma industry’s biggest companies have over the last week added to their condemnation of Russia’s invasion of Ukraine by declaring a halt to investment in the country and suspension of clinical trials.
But while the sector wants to abide by the spirit of international sanctions imposed on Russia, suspension of trials in the country have much more to do with the logistical problems caused by the escalating
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?